Pancreatic Cancer Research

ResearcherUniversity of Wisconsin–MadisonActive in the last 2 years

Sean M. Ronnekleiv‐Kelly

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6664-996X; OpenAlex author ID A5032788721. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
20
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 8

  1. Neoadjuvant Stereotactic Body Radiation Therapy Plus Elective Nodal Irradiation With Concurrent Capecitabine for Patients With Resectable Pancreatic Cancer: Su… Co-author DOI 10.1016/j.prro.2025.01.011↗
  2. Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer. Co-author DOI 10.1016/j.medj.2024.02.012↗
  3. Aryl Hydrocarbon Receptor Knockout Accelerates PanIN Formation and Fibro-Inflammation in a Mutant Kras -Driven Pancreatic Cancer Model. Last author DOI 10.1097/mpa.0000000000002357↗
  4. The circadian clock is disrupted in pancreatic cancer. Last author DOI 10.1371/journal.pgen.1010770↗
  5. A Phase 1 Dose Escalation Study of Neoadjuvant SBRT Plus Elective Nodal Radiation with Concurrent Capecitabine for Resectable Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2020.09.010↗
  6. National Trends in Centralization of Surgical Care and Multimodality Therapy for Pancreatic Adenocarcinoma. Co-author DOI 10.1007/s11605-019-04361-3↗
  7. Natural History and Treatment Trends in Pancreatic Cancer Subtypes. Co-author DOI 10.1007/s11605-019-04113-3↗
  8. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6650-z↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Patrick Beard Schwartz · 3 shared papers, 2023–2024 · strength 0.64
  2. Daniel Erik Abbott · 5 shared papers, 2018–2025 · strength 0.62
  3. Sharon Marie Weber · 5 shared papers, 2018–2025 · strength 0.62
  4. Michael Frederick Bassetti · 2 shared papers, 2021–2025 · strength 0.31
  5. Noelle K. LoConte · 2 shared papers, 2021–2025 · strength 0.31
  6. Jacob S. Witt · 2 shared papers, 2021–2025 · strength 0.31
  7. Nataliya Volodymyrivna Uboha · 2 shared papers, 2021–2025 · strength 0.31
  8. Alexander V. Fisher · 3 shared papers, 2018–2020 · strength 0.31
  9. Morgan T. Walcheck · 1 shared paper, 2024 · strength 0.24
  10. Jeremy D. Kratz · 1 shared paper, 2025 · strength 0.20
  11. Mustafa M. Basree · 1 shared paper, 2025 · strength 0.20
  12. Syed Nabeel Zafar · 1 shared paper, 2025 · strength 0.20
  13. Zhaoting Li · 1 shared paper, 2024 · strength 0.20
  14. Yu Chen · 1 shared paper, 2024 · strength 0.20
  15. Kai Guo · 1 shared paper, 2024 · strength 0.20
  16. Quanyin Hu · 1 shared paper, 2024 · strength 0.20
  17. Shuai Ren · 1 shared paper, 2024 · strength 0.20
  18. Emily R. Winslow · 2 shared papers, 2018–2019 · strength 0.19
  19. Yue Ma · 1 shared paper, 2020 · strength 0.12
  20. Courtney J. Pokrzywa · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.